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Abstract 
Central  nervous  system  (CNS)  lymphoma
involving the dura mater is very rare and histo-
logically is usually a subtype of non-Hodgkin’s
lymphoma  (NHL)  termed  mucosa-associated
lymphoid tissue (MALT) lymphoma. We pres-
ent a case of a 46-year old woman with dural
MALT lymphoma that was found to also involve
a lacrimal gland, inguinal lymph nodes, and
bone marrow. Magnetic resonance imaging of
the  brain  showed  an  extra-axial  enhancing
mass approximately 6 cm in maximum diame-
ter along the right frontotemporal convexity.
Histopathology  of  the  resected  dural  mass
showed  MALT  lymphoma  expressing  CD20,
CD52, CD19, and CD38. Molecular studies of
the B-cell receptor heavy chain demonstrated
monoclonality  at  the  involved  sites.  The
patient was treated with four cycles of fludara-
bine, mitoxantrone, and rituximab with com-
plete  remission.  She  had  recurrence  in  the
subcutaneous tissue of the back at 12 months
but has remained free of intracranial disease
for  31  months.  A  review  of  the  literature
reveals  57  cases  of  dural  MALT  lymphoma.
Only 4 had extra-CNS involvement at presenta-
tion, and only 3 had local recurrence of the
dural tumor. Because of the indolent behavior
of this tumor, the intracranial portion can be
treated conservatively after resection with or
without chemotherapy. Deferral of brain radia-
tion can be considered with close clinical and
neuroimaging follow up.
Introduction 
Central nervous system (CNS) involvement
with  non-Hodgkin’s  lymphoma  (NHL)  falls
into one of three categories: primary CNS lym-
phomas  (PCNSL),  disseminated  lymphoma
with CNS involvement, and primary dural lym-
phoma. Primary CNS lymphomas are typically
diffuse large B-cell lymphomas and are found
in the brain parenchyma and other CNS struc-
ture.1 Disseminated  lymphoma  typically
involves  the  meninges  in  a  leptomeningeal
pattern  similar  to  leukemia.2 It  can  also  be
found intraparenchymally but does not typical-
ly occur within the dura.2-4 A small proportion
of CNS lymphomas are extraaxial, intradural
lymphomas  that  typically  do  not  involve  the
brain parenchyma.5 The vast majority of these
are low grade extranodal marginal zone lym-
phomas,  also  called  mucosa-associated  lym-
phoid  tissue  (MALT)  lymphomas  (primary
dural  marginal  zone  lymphoma,  PDMZL),5,6
although a small number of higher grade lym-
phomas have been reported including diffuse
large  B-cell  and  follicular  lymphoma.5
Distinguishing among types of CNS lymphoma
can be difficult, and the distinction is some-
times obscured in the literature due to lump-
ing of all meningeal lymphomas together. In
this review, a dural lymphoma refers to a solid,
localized  mass,  within  or  indistinguishable
from the dura mater, that radiographically may
have a dural tail. In contrast, leptomeningeal
lymphoma is diffusely spread over the surface
of the brain, involving the other meningeal lay-
ers but not primarily the dura. When defined in
this way, dural lymphoma is relatively rare.
We now report a case of disseminated MALT
lymphoma with involvement of the dura and
discuss the management of this case in light of
the current available literature on such cases. 
Case Report
A  46-year  old  right  handed  Caucasian
female  presented  with  a  small  lump  in  her
right upper inner eyelid. This was initially dis-
missed, but the patient presented again with
pressure symptoms in the right frontal region
of her head and blurring of vision of the right
eye. An MRI of the brain showed a 2¥6¥6 cm
extra-axial  enhancing  mass  along  the  right
frontal convexity, extending anteriorly to the
superior ridge of the orbit. There was no sig-
nificant edema around the lesion, which was
initially felt to be consistent with an en plaque
meningioma (Figure 1). On further review, the
lesion was found to be extending across the
midline with thickening and enhancement of
the  left  frontal  dura  mater.  There  was  also
increased  T2  signal  in  the  adjacent  cortical
sulci with subtle contrast enhancement. The
overlying bone marrow also showed abnormal
signal, indicative of an infiltrative process. The
patient was referred to our institution for a
second opinion regarding diagnosis and man-
agement. On physical exam she was neurolog-
ically intact and positive findings included a
small nodule palpable in the right upper palpe-
bra in a supranasal location. She had no palpa-
ble  lymphadenopathy  except  shotty  inguinal
nodes. The dural mass was resected via a right
frontal craniotomy. The pathology was consis-
tent with MALT lymphoma expressing CD20,
CD52,  CD19,  and  CD38,  but  not  CD5,  with
kappa light chain restriction (Figure 2).  
A PET-CT scan of the whole body showed
shotty  cervical,  axillary,  and  inguinal  lymph
nodes  that  demonstrated  mildly  increased
metabolic activity -standardized uptake value
(SUV) in the 2-4 range with the highest values
in inguinal regions. A biopsy of a left inguinal
node showed lymphoid proliferation and flow
cytometry  studies  were  consistent  with  a
kappa-restricted  B-cell  neoplastic  prolifera-
tion. The patient also had an anterior orbitoto-
my and biopsy of the orbital mass that demon-
strated  lacrimal  gland  involvement  by  MALT
lymphoma  with  the  same  immunophenotype
as the lymph node and the dural mass. Bone
marrow  biopsy  showed  a  small  population
(2.6% of nucleated cells) of kappa-restricted B-
lymphocytes by flow cytometry, but spinal fluid
was negative. 
For the tissue taken from the orbit, the dura
and the lymph nodes, PCR amplification of the
variable  region  of  the  B-cell  receptor  heavy
chain  (according  to  published  methods,7)
resulted in a single band of about 250 base
pairs on gel electrophoresis (Figure 3). PCR of
the bone marrow failed to yield a defined sin-
gle  band.    The  PCR  products  were  sent  for
sequencing, and sequence analysis indicated
that the sequences from the orbit and the dura
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had  99.2%  identity.  The  sequence  from  the
lymph nodes was of lesser quality, but also had
a very high identity with the dural sequence
(80.1%), indicating that the lymphoid cells in
these tissues were clonally related.
The  patient  was  treated  with  intravenous
fludarabine,  mitoxantrone,  and  rituximab
every four weeks for a total of four cycles. The
patient did not receive radiation treatment to
the dural lesion; the decision was made to fol-
low her closely with serial MRIs to monitor for
intracranial recurrence.
The  patient  relapsed  with  biopsy-proven
MALT  lymphoma  in  subcutaneous  tissues  of
the back and buttock 12 months after diagno-
sis. A bone marrow biopsy at that time was
negative for malignancy. She was treated with
additional rituximab and then maintained on
rituximab. At 33 months since diagnosis she is
again in complete remission and has remained
free of CNS disease.
Materials and Methods
Several  thick  slices  of  paraffin  embedded
tissue were provided by the pathology laborato-
ry.  Genomic  DNA  was  extracted  using  the
Qiagen DNeasy Blood & Tissue kit. Semi-nest-
ed  PCR  was  performed  as  previously






Primers were ordered from Integrated DNA
Technologies (IDT®). PCR conditions were as
follows: denaturation at 94°C for 5 min, fol-
lowed by 40 cycles of 94°C for 2 min, 50°C for
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Figure 1. Brain MR imaging. (a) Post-contrast axial T1-weighted image shows a homoge-
nously enhancing extra-axial dural-based mass (m) in the right frontal region. The thicken-
ing and enhancement of the dura extends anteriorly along the falx and along the left frontal
lobe (long arrows). There is also subtle enhancement extending into a few of the adjacent
cortical sulci (short arrows). (b) Corresponding axial fluid-attenuated inversion recovery
(FLAIR) image reveals abnormal hyperintensity within the cortical sulci (arrows) adjacent
to the lesion, corresponding to subtle enhancement in A). (c) Non-enhanced axial T1-
weighted image at a slightly higher level demonstrates loss of normal bone marrow hyper-
intensity in the calvarium adjacent to the dural mass and in the left parietal bone (long
arrows). Note normal bright bone marrow (short arrows). (d)  Corresponding diffusion-
weighted image (DWI) reveals signal intensity similar to the dural mass within the affected
bone marrow (long arrows). Note normal bone marrow without any signal (short arrows).
(e) Corresponding apparent diffusion coefficient (ADC) map shows that the diffusion of
water molecules within the affected bone marrow is similar to the dural lesion (long arrows).
Normal bone marrow remains black without any signal (short arrows).
Figure 2. Morphology and immunohisto-
chemical staining of dural mucosa-associ-
ated  lymphoid  tissue  (MALT  lymphoma)
(a) At low magnification there is a diffuse
lymphocytic infiltration of the dura with
characteristic  perivascular  pattern.    Folli  -
cular structures were not identified. (origi-
nal  magnification  x100).  (b)  At  higher
magnification  the  neoplastic  cells  can  be
seen  to  exhibit  a  morphologic  spectrum
with  abundant  pale  agranular  cytoplasm
and  small  to  medium-sized  nuclei  with
round to irregular nuclear borders.  Rare
large centroblast-like cells and plasma cells
are present (original magnification x400).
(c)  CD20  immunohistochemical  stain
shows diffuse positivity (original magnifi-
cation x50). (d) CD3 immunohistochemi-
cal stain shows only scattered positive cells
(original magnification x50).[page 50] [Hematology Reports 2010; 2:e10]
2 min, and 72°C for 2 min, followed by elonga-
tion at 72°C for 20 min. Genomic DNA was first
amplified with the FR2a and LJH primers, then
a  1:5000  dilution  of  the  PCR  product  was
amplified  with  the  FR2a  and  VLJH  primers.
Products were analyzed by electrophoresis on a
2%  agarose  gel  and  then  extracted  using
Qiaquick  Gel  Extraction  Kit®.  PCR  products
were  sent  for  sequencing  at  the  MUSC
Biotechnology  Resource  Laboratory.  Some
sequences were corrected by visually calling
nucleotides  from  the  chromatogram  using
ChromasLite 2.01 from Technelysium Pty Ltd.©
(http://www.technelysium.com.au). Sequen  ces
were  analyzed  using  Biology  Workbench  3.2
(http://seqtool.sdsc.edu).
Discussion
This report describes a patient with dissem-
inated low grade MALT lymphoma that involved
the  dura.  The  histological  evidence  showed
that a B-cell malignancy was disseminated at
presentation,  involving  the  lacrimal  gland,
lymph  nodes,  bone  marrow  and  intracranial
dura.  Examination  of  all  of  these  tissues
revealed a MALT lymphoma. This tissue distri-
bution suggests that the patient had a subclin-
ical MALT lymphoma that became disseminat-
ed.  Laboratory  studies  proved  that  the  lym-
phoid proliferations were neoplastic and not
reactive  or  inflammatory  processes.  PCR
amplification of the IGH variable region in the
samples from dura, lymph node and lacrimal
gland demonstrated a single band of the same
size,  indicating  monoclonality.  In  addition,
sequencing of this segment demonstrated fur-
ther that the gene rearrangement was identi-
cal in this region. 
Dural  lymphomas  pose  special  diagnostic
and therapeutic challenges. Because they are
uncommon,  they  are  often  initially  misdiag-
nosed as meningiomas or other lesions based
on imaging.3,9-42 Intracranial lymphomas may
be  epidural,  dural,  subdural,  subarachnoid,
and combinations of these.43 A dural mass with
associated  leptomeningeal  and/or  bone  mar-
row imaging abnormalities is highly unusual
for  meningioma  and  is  suggestive  of  lym-
phoma  or  metastatic  malignancy.  Since  the
therapy for meningioma and dural lymphoma
are different, several authors have stressed the
importance of getting a tissue diagnosis before
treatment  of  a  dural  lesion  identified  on
MRI.15,31,33,44
The majority of dural lymphomas are MALT
lymphomas.5 MALT lymphoma is a type of B-
cell lymphoma that has the characteristics of
marginal zone cells and typically arises from
nests  of  lymphoid  cells  in  mucosal  tissues.
Occasionally it is found to arise in non-mucos-
al sites such as skin, orbit or dura.45,46 MALT
lymphoma  was  originally  described  by
Isaacson and Wright in 1983.47 Since that time,
clinical experience with this entity has steadi-
ly grown, as has the understanding of its etiol-
ogy  and  pathogenesis.  According  to  the
Revised European – American Classification of
Lymphoid Neoplasms (REAL) and the subse-
quent update by the World Health Organization
(WHO),  Classification  of  Neoplasms  of  the
Hematopoietic and Lymphoid Tissues, margin-
al zone B-cell lymphomas are a histologic cate-
gory  of  the  mature  peripheral  B-cell  neo-
plasms.48,49 Marginal  zone  B-cell  lymphomas
(MZLs)  are  further  divided  clinically  into
nodal,  extranodal,  and  splenic  types.
Extranodal marginal zone B-cell lymphoma is
equivalent to MALT lymphoma. While the earli-
er REAL classification considered extranodal
and nodal MZLs to be histologically the same,
only distinguishable by their clinical presenta-
tion,  the  newer  WHO  classification  regards
nodal MZLs to be a distinct entity with a worse
prognosis  than  extranodal/MALT  MZLs  with
nodal involvement.48,49 MALT lymphomas usu-
ally arise in the gastrointestinal tract, especial-
ly the stomach, but are also found in the head
and  neck  region  (orbital  tissues,  salivary
glands, and thyroid), skin, and lung.
MALT lymphoma generally has a good prog-
nosis and can be treated with minimally toxic
methods.5,50,51 While MALT lymphoma usually
remains localized for a long time, retrospective
studies  have  shown  that  one  third  to  one
fourth of non-gastrointestinal cases had dis-
seminated  disease  at  diagnosis.46,50,51 One
report indicates that MALT lymphomas arising
in non-gastrointestinal tract locations have a
higher rate of dissemination that those arising
in the GI tract.52 MALT lymphomas have a ten-
dency  to  spread  to  non-contiguous  mucosa
associated  sites.52 Whether  disseminated
MALT  lymphoma  carries  a  poorer  prognosis
than localized disease is a subject of debate. In
a series of patients studied by Arcaini et al.,45
dissemination to lymph nodes or bone marrow
was associated with shorter overall survival,
while Thieblemont et al. found no difference in
outcome between patients with disseminated
versus localized disease.51,53
While  MALT  lymphomas  remain  indolent,
there  is  a  risk  of  transformation  to  higher
grade lymphomas. In most cases, MALT lym-
phomas have been reported to transform into
diffuse large B-cell lymphoma,54-57 which has a
much  worse  prognosis.  Indolent  lymphomas
transform into higher grade lymphomas at a
rate of 3% per year.58
No evidence based guidelines exist for treat-
ing MALT and the other types of marginal zone
lymphoma,  but  current  treatment  strategies
have  been  reviewed  by  Thieblemont  and
Coiffier.45 Localized  disease  that  is  clearly
linked  to  an  infectious  stimulus  (such  as
Helicobactor pylori in gastric MALT lymphoma)
has been treated with antibiotics as the sole
initial treatment, resulting in complete remis-
sion, although it is uncertain if this complete-
ly  eradicates  neoplastic  cells.  For  localized
MALT that is not linked to an infectious stimu-
lus, localized treatment with surgery or radia-
tion  has  been  successful.  For  disseminated
disease, a number of chemotherapeutic agents
have  been  tried,  including  corticosteroids,
alkylating agents (cyclophosphamide and chlo-
rambucil), nucleoside analogues (fludarabine
and  cladribine),  doxorubicin,  mitoxantrone,
and rituximab, alone or in combination.45,59-61
The clinician encountering a patient with
dural MALT lymphoma has little guidance on
what therapies might be effective in control-
ling the disease and if, in fact, radiation or
cytotoxic treatment is warranted after resec-
tion, given the indolent nature of the disease
and the potential for CNS toxicity. Radiation
has been considered a preferred therapy for
localized dural MALT lymphoma because it is a
very radiosensitive tumor, and a local modality
of treatment is appropriate for a tumor that
generally remains localized. However, there is
no consensus on dose and schedule, and irra-
diation of the brain has significant side effects
and  must  be  used  judiciously,  especially  in
young  to  middle  aged  patients  who  are  at
increased risk of early dementia.  In the case of
a dural MALT lymphoma that is not localized,
radiation may be less preferred because the
patient must receive systemic therapy for the
disseminated disease and additional therapy
may not be necessary.
An interesting feature of the lymphoma in
this case is the unusual tissue distribution. As
described  above,  MALT  lymphoma  is  usually
indolent  and  rarely  becomes  disseminated.
Case Report
Figure 3. PCR amplification of the vari-
able  region  of  the  B-cell  receptor  heavy
chain resulted in a single band for tissue
taken  from  the  orbit,  lymph  node  and
dura,  demonstrating  that  rearrangement
has occurred and the B-cells are monoclon-
al.  PCR of the bone marrow failed to yield
a defined single band.  [Hematology Reports 2010; 2:e10]
Dural MALT lymphoma is almost always local-
ized,  without  systemic  involvement.  Only  4
cases  have  been  reported  with  involvement
outside of the CNS on presentation;10,35,62 this
case is the fifth. In two of these cases, the only
extra-CNS  involvement  was  in  the  ocular
adnexa, with presumed contiguous spread to
the globe, the optic nerve, cavernous sinus and
the dura.10
Dural lymphoma is relatively rare, and most
of the reported cases are of dural MALT, the
most common type. Here we attempt to sum-
marize the available literature on dural lym-
phoma. A literature search found 93 cases of
dural based lymphomas (Table 1). Of these, 67
(72%)  were  described  as  MALT  or  marginal
zone lymphoma,6,9,10,12,15,16,20-25,28-35,41,44,62-70 9 were
diffuse  large  B-cell  lymphoma,11,14,18,27,36,37,42,71
and 6 were follicular lymphoma.3,17,26,38,40,72 Six
were  described  as  small  lymphocytic  lym-
phoma13,14,73,74 or B-cell lymphoproliferative dis-
order of CLL type,75 but the four of these that
were described prior to the establishment of
the REAL-WHO criteria may have actually been
MALT/Marginal  zone  lymphoma  since
immunophenotypical  analysis  was  not  per-
formed.15,74 The  remaining  5  cases  were
described in various ways, including large-cell
immunoblastic T-cell lymphoma,14 monocytoid
malignant  B-cell  lymphoma,76 centroblastic/
centrocytic lymphoma,19 precursor B-cell lym-
phoblastic lymphoma,77 and diffuse large cell
non-Hodgkin lymphoma due to Richter’s trans-
formation.39 Of the cases of dural MALT lym-
phoma/MZL,  63  (94%)  were  isolated  to  the
CNS, while only 4 (6%) were associated with
extra-CNS disease at the time of diagnosis. An
additional 5 cases subsequently became dis-
seminated. Of the non-MALT dural lymphomas,
20  (77%)  were  isolated  to  the  dura,  and  6
(23%) were associated with disseminated dis-
ease. While these numbers are small, they sug-
gest  that  dural  MALT  lymphomas  are  highly
likely to remain as primary dural tumors and
not spread to other tissues. Other dural lym-
phomas appear to have a higher incidence of
either arising in the context of a disseminated
lymphoma, or arising in the dura and subse-
quently disseminating. 
Of the 57 cases of dural MALT lymphoma
that have outcomes reported after partial or
total surgical resection, only 3 had local recur-
rence  in  the  dura,  and  only  6  had  systemic
recurrence (Table 2). Of those receiving radia-
tion, 1 out of 47 had local recurrence. Of those
receiving chemotherapy, 3 out of 21 had local
recurrence  (17  patients  received  both
chemotherapy and radiation). Of those receiv-
ing chemotherapy alone, 2 out of 4 had local
recurrence.  None  of  the  4  patients  who
received neither chemotherapy nor radiation
had  local  or  systemic  recurrence.  Follow-up
was highly variable, but average progression
free  survival  for  dural  MALT  lymphoma  was
greater than 29 months. Of the four patients
who had extra-CNS disease at presentation, 1
received chemotherapy only, 1 received radia-
tion only and the other two received radiation
and chemotherapy.
These numbers, while small, suggest that
local recurrence is uniformly rare after surgi-
cal resection. Local recurrence occurred slight-
ly more frequently with chemotherapy alone
than with radiation alone, however the signif-
icance of this is unclear since there were only
3 instances of local recurrence in the entire
series. In two of the three cases of local recur-
rence, the patients were salvaged with addi-
tional  chemotherapy  with  complete
response.10,31 Puri et al. propose involved field
radiation  (IFRT)  as  an  effective  means  to
locally control dural MALT lymphoma, however
it is unclear whether even the reduced toxicity
of IFRT is justified in a disease that so rarely
has local recurrence.6 In the current case, the
patient  received  systemic  chemotherapy  for
her  disseminated  disease,  which  may  have
also served to control her dural tumor since the
dura is not protected by the blood-brain barri-
er. Based on the published experience, the cli-
nician encountering a dural MALT lymphoma,
with or without dissemination, must carefully
weigh the need for radiotherapy, but may con-
sider deferring radiotherapy, with close follow-
up.  This  is  especially  true  in  the  setting  of
complete resection or systemic chemotherapy.
Conclusions
This case of disseminated MALT lymphoma
with involvement of the dura demonstrates the
importance of maintaining a wide differential
diagnosis for dural lesions with imaging char-
acteristics  that  appear  typical  for  a  menin-
gioma. Careful analysis of the imaging studies,
primarily  MRI,  frequently  offers  additional
information,  detecting  the  imaging  findings
that are suggestive of other disease processes,
such as lymphoma. A biopsy and tissue diagno-
sis should be obtained and complete staging
should  be  done.  Dural  MALT  lymphomas
appear to have a very low incidence of local
recurrence and therefore irradiation may not
be  necessary;  close  surveillance  is  a  valid
option for managing this indolent tumor.
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